Mesothelioma Essential Update 2019

posted in: Blog | 0

March 2019 By Liz Darlison, Head of Services and Clinical Nurse Specialist for Mesothelioma UK and Professor James Spicer, BTOG Steering Committee Member. An Essential Update on mesothelioma, organised by the British Thoracic Oncology Group and Mesothelioma UK, was held … Read More

WCLC Highlights

posted in: Blog | 0

October 2018 By James Spicer, Professor of Experimental Cancer Medicine and Consultant in Medical Oncology ALTA1: brigatinib vs crizotinib in ALK-rearranged non-small cell lung cancer The initial results of this comparison of brigatinib with the first generation drug crizotinib were presented … Read More

NICE approves Alectinib as first line treatment for ALK-translocated NSCLC

July 2018 By Tom Newsom-Davis, Consultant Oncologist NICE has just approved Alectinib as first line treatment for ALK-translocated NSCLC. https://www.nice.org.uk/guidance/gid-ta10206/documents/final-appraisal-determination-document This is exciting news for patients with this comparatively rare type of lung cancer. Currently the standard of care in the … Read More